In a 10-patient cohort study led by Dr. Jean Roy, hematologist and professor at the Faculty of Medicine of Université de Montréal, that aims to understand how to mitigate the risks associated with the treatment of multiple myeloma, a malignant cancer, researchers have adopted an innovative approach based on the unique immunological properties of umbilical cord blood in an effort to improve the safety and efficiency of allografting, the preferred treatment for this disease.

The FDA approved an investigational new drug application from Cellectis for a Phase 1 clinical trial of UCART22, its third gene-edited CAR-T cell candidate.

Christiana Care has been talking with the U.S. Food & Drug Administration about developing a gene editing tool called CRISPR to assist in lung cancer treatments. One question they?ll face in the future is if insurance companies will pick up the cost.

Award? goes to biochemists Virginijus Siksnys, whose lab independently developed the gene-editing tool, Emmanuelle Charpentier and Jennifer Doudna.

For more information, you can visit the festival?s website at: stemcellfestival.com

In research published today in the journal Cell Stem Cell, scientists at Columbia University Vagelos College of Physicians and Surgeons present the most definitive evidence to date that the human brain makes new neurons throughout life.

A new Japanese joint venture company called MAGiQ Therapeutics ? the result of a collaboration between Q Therapeutics and Reprocell ? aims to develop cell and gene therapies for demyelinating and degenerative diseases of the central nervous system.

The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) ? a CAR-T cell therapy ? for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).

. By using this method, scientists from the German Primate Center (DPZ) __ Leibniz Institute for Primate Research have discovered a quicker and more efficient treatment for the cells.

The incidence of heart disease is on the rise, and new therapeutic strategies are needed. Approaches based on stem cells, which can potentially preserve or even regenerate heart muscle cells damaged by ischemia ? a hallmark of heart disease ? are especially promising. Now, thanks to an $11.6-Million Program Project Grant (PPG) from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under award number P01HL134608, scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) are poised to explore new possibilities in stem cell-based treatments for heart repair and regeneration.